Selecta Biosciences Inc., of Watertown, Mass., said the FDA accepted the IND for a combination therapeutic candidate consisting of SVP-Rapamycin and LMB-100 (Selecta's SEL-403 product candidate) for the treatment of mesothelioma patients.